Hostname: page-component-78c5997874-v9fdk Total loading time: 0 Render date: 2024-11-05T10:15:33.346Z Has data issue: false hasContentIssue false

Aging of the Nigrostriatal Pathway in Humans

Published online by Cambridge University Press:  05 January 2016

Donald B. Calne*
Affiliation:
Department of Medicine, Division of Neurology, Health Sciences Centre Hospital, University of British Columbia, Vancouver
R.F. Peppard
Affiliation:
Department of Medicine, Division of Neurology, Health Sciences Centre Hospital, University of British Columbia, Vancouver
*
Division of Neurology, Health Sciences Centre Hospital, 2211 Westbrook Mall, U.B.C., Vancouver, B.C. V6T 1W5
Rights & Permissions [Opens in a new window]

Abstract:

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

Progressive degeneration of functionally related groups of neurons occurs in certain infective, toxic, nutritional and genetically determined neurological diseases. It also takes place in normal aging, and several of the regions that undergo selective decay with the passage of time seem to be the same target regions that are afflicted in degenerative disorders such as Parkinson's disease, Alzheimer's disease and amyotrophic lateral sclerosis (ALS). Infective etiology is relatively easy to exclude by a combination of immunological tests and transfer experiments. Genetic causation can be rendered unlikely when large kindreds are available for study. Nutritional deprivation and acute or subacute toxicity are accessible to explanation by examining the environment. The most difficult mechanism of pathogenesis to refute is chronic toxic damage, where the lesion may derive from long-term exposure to a relatively widespread noxious agent or agents. Variations in involvement of individuals within a population may stem from differing capacities to activate or inactivate a toxin. Inherent in this concept of etiology is recognition that compensatory potential within the central nervous system may contribute to prolonged existence of subclinical lesions so that a latent period may exist for several decades, between causal event and the onset of symptoms. Furthermore, progressive clinical deterioration may take place even though the cause may have been transient, many years before. The histological features associated with Parkinson's disease, Alzheimer's disease and ALS may be nonspecific indicators of neuronal “illness”, there being a predilection for certain morphological markers to appear more frequently in particular circumstances and particular regions associated with the pathology of particular diseases.

Type
Research Article
Copyright
Copyright © Canadian Neurological Sciences Federation 1987

References

REFERENCES

1.Calne, DB, Eisen, A, Stoessl, AJ, et al. Alzheimer’s disease, Parkinson’s disease, and motorneuron disease: Abiotropic interaction between aging and environment? The Lancet 1986; 2: 10671070.CrossRefGoogle Scholar
2.McGeer, PL, McGeer, E, Suzuki, JS. Aging and extrapyramidal function. Arch Neurol 1977; 34: 3335.CrossRefGoogle ScholarPubMed
3.Cote, LJ, Kremzner, LT.Biochemical changes in normal aging in human brain. In: Mayeux, R, Rosen, WG, eds. Advances in Neurology. Volume 38. The dementias. Raven Press, New York, 1983; 1930.Google Scholar
4.Carlsson, A, Winblad, B.Influence of age and time interval between death and autopsy on dopamine and 3-methoxytyramine levels in human basal ganglia. J Neural Transm 1976; 38: 271276.CrossRefGoogle ScholarPubMed
5.Carlsson, A, Nyberg, P, Winblad, B.The influence of age and other factors on concentrations of monoamines in the human brain. In: Nyberg, P, ed. Brain monoamines in normal aging and dementia. Umea University Medical Dissertations, Sweden, 1984; 5384.Google Scholar
6.Severson, JA, Marcusson, J, Winblad, B, et al. Age-correlated loss of dopaminergic binding sites in human basal ganglia. J Neurochem 1982; 39: 16231631.CrossRefGoogle ScholarPubMed
7.Wong, DF, Wagner, HN Jr, Dannals, RF, et al. Effects of age on dopamine and serotonin receptors measured by positron tomography in the living human brain. Science 1984; 226: 13931396.CrossRefGoogle ScholarPubMed
8.Mann, DMA, Yates, PO.Possible role of neuromelanin in the pathogenesis of Parkinson’s disease. Mechanisms of Aging and Development 1983; 21: 193203.CrossRefGoogle ScholarPubMed
9.Mann, DMA.Dopamine neurones of the vertebrate brain: Some aspects of anatomy and pathology. In: Winlow, W, Markstein, R, eds. The neurobiology of dopamine systems. Manchester University Press, Manchester, 1984; 87103.Google Scholar
10.Riederer, P, Wuketich, ST.Time course of nigrostriatal degeneration in Parkinson’s disease. J Neural Transm 1976; 38: 277301.CrossRefGoogle ScholarPubMed
11.Bernheimer, H, Birkmayer, W, Hornykiewicz, O, et al. Brain dopamine and the syndromes of Parkinson and Huntington. J Neurol Sci 1973; 20: 415455.CrossRefGoogle ScholarPubMed